Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Bought by Aigen Investment Management LP

Aigen Investment Management LP increased its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 56.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,072 shares of the company’s stock after purchasing an additional 6,892 shares during the quarter. Aigen Investment Management LP’s holdings in Travere Therapeutics were worth $332,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Victory Capital Management Inc. acquired a new stake in shares of Travere Therapeutics in the 4th quarter worth approximately $182,000. Charles Schwab Investment Management Inc. lifted its position in Travere Therapeutics by 16.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 661,603 shares of the company’s stock worth $11,525,000 after purchasing an additional 94,194 shares during the period. US Bancorp DE boosted its stake in Travere Therapeutics by 323.4% during the 4th quarter. US Bancorp DE now owns 31,795 shares of the company’s stock valued at $554,000 after purchasing an additional 24,286 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Travere Therapeutics by 3.6% during the 4th quarter. Bank of New York Mellon Corp now owns 216,863 shares of the company’s stock valued at $3,778,000 after purchasing an additional 7,513 shares in the last quarter. Finally, Impax Asset Management Group plc acquired a new position in shares of Travere Therapeutics during the 4th quarter valued at $5,226,000.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock opened at $18.09 on Friday. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $25.29. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The stock has a market cap of $1.61 billion, a PE ratio of -4.41 and a beta of 0.75. The business has a fifty day simple moving average of $20.24 and a 200-day simple moving average of $17.42.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). The business had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. On average, sell-side analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CAO Sandra Calvin sold 15,000 shares of the company’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP William E. Rote sold 2,437 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $47,424.02. Following the sale, the senior vice president now owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 206,335 shares of company stock worth $4,453,012. 3.75% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TVTX. Scotiabank upped their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Canaccord Genuity Group increased their target price on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Finally, Citigroup lifted their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $30.62.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.